LT3108886T - Cc-1065 analogų ir bifunkcinių jungtukų konjugatai - Google Patents

Cc-1065 analogų ir bifunkcinių jungtukų konjugatai

Info

Publication number
LT3108886T
LT3108886T LTEP16176625.8T LT16176625T LT3108886T LT 3108886 T LT3108886 T LT 3108886T LT 16176625 T LT16176625 T LT 16176625T LT 3108886 T LT3108886 T LT 3108886T
Authority
LT
Lithuania
Prior art keywords
conjugates
analogs
bifunctional linkers
linkers
bifunctional
Prior art date
Application number
LTEP16176625.8T
Other languages
English (en)
Inventor
Patrick Henry Beusker
Rudy Gerardus Elisabeth Coumans
Ronald Christiaan Elgersma
Wiro Michael Petrus Bernardus Menge
Johannes Albertus Frederikus Joosten
Henri Johannes Spijker
Franciscus Marinus Hendrikus GROOT de
Original Assignee
Syntarga B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntarga B.V. filed Critical Syntarga B.V.
Publication of LT3108886T publication Critical patent/LT3108886T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP16176625.8T 2010-04-21 2011-04-21 Cc-1065 analogų ir bifunkcinių jungtukų konjugatai LT3108886T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32643710P 2010-04-21 2010-04-21
US42182410P 2010-12-10 2010-12-10

Publications (1)

Publication Number Publication Date
LT3108886T true LT3108886T (lt) 2020-08-25

Family

ID=44343209

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP11720340.6T LT2560645T (lt) 2010-04-21 2011-04-21 Cc-1065 analogų ir bifunkcinių linkerių konjugatai
LTEP16154533.0T LT3056203T (lt) 2010-04-21 2011-04-21 Konjugatai cc-1065 analogų ir bifunkcinių linkerių
LTEP16176625.8T LT3108886T (lt) 2010-04-21 2011-04-21 Cc-1065 analogų ir bifunkcinių jungtukų konjugatai

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP11720340.6T LT2560645T (lt) 2010-04-21 2011-04-21 Cc-1065 analogų ir bifunkcinių linkerių konjugatai
LTEP16154533.0T LT3056203T (lt) 2010-04-21 2011-04-21 Konjugatai cc-1065 analogų ir bifunkcinių linkerių

Country Status (23)

Country Link
US (3) US9629924B2 (lt)
EP (3) EP2560645B1 (lt)
JP (2) JP6009434B2 (lt)
KR (3) KR20170027880A (lt)
CN (1) CN106749665B (lt)
AU (2) AU2011243294C1 (lt)
BR (1) BR112012026953A8 (lt)
CA (2) CA2956934C (lt)
CY (3) CY1118072T1 (lt)
DK (3) DK3056203T3 (lt)
ES (3) ES2815678T3 (lt)
HR (3) HRP20161339T1 (lt)
HU (3) HUE050508T2 (lt)
LT (3) LT2560645T (lt)
MX (2) MX336853B (lt)
NO (1) NO3056203T3 (lt)
PL (3) PL3108886T3 (lt)
PT (3) PT3056203T (lt)
RU (2) RU2730502C2 (lt)
TR (1) TR201802539T4 (lt)
UA (1) UA112291C2 (lt)
WO (1) WO2011133039A2 (lt)
ZA (1) ZA201208282B (lt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596295A (en) 2006-03-10 2013-01-25 Wyeth Corp Anti-5T4 antibodies and uses thereof
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
MX2011004625A (es) 2008-11-03 2011-07-20 Syntarga Bv Analogos cc-1065 novedosos y sus conjugados.
CA2956934C (en) 2010-04-21 2019-07-09 Syntarga B.V. Novel conjugates of cc-1065 analogs and bifunctional linkers
ES2738310T3 (es) 2012-10-12 2020-01-21 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
KR20150119848A (ko) 2012-12-21 2015-10-26 바이오얼라이언스 씨.브이. 친수성 자기-희생 링커 및 그것의 포합체
AU2014244245C1 (en) * 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
JP6993084B2 (ja) 2013-08-12 2022-02-03 ジェネンテック， インコーポレイテッド １－（クロロメチル）－２，３－ジヒドロ－１ｈ－ベンゾ［ｅ］インドール二量体抗体 － 薬物コンジュゲート化合物、並びに使用及び処置の方法
EP3082876B1 (en) 2013-12-16 2018-01-17 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
MX368396B (es) * 2014-01-10 2019-10-01 Synthon Biopharmaceuticals Bv Conjugados de anticuerpo-farmaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada.
AU2015205574B2 (en) 2014-01-10 2019-08-15 Byondis B.V. Method for purifying Cys-linked antibody-drug conjugates
HRP20160797T1 (hr) * 2014-01-10 2016-08-12 Synthon Biopharmaceuticals B.V. Duokarmicin adsc, namijenjen upotrebi u liječenju raka endometrija
SG10201913977TA (en) 2014-05-22 2020-03-30 Synthon Biopharmaceuticals Bv Site-specific conjugation of linker drugs to antibodies and resulting adcs
PT3152191T (pt) 2014-06-05 2019-08-30 Synthon Biopharmaceuticals Bv Processo melhorado para preparar profármacos de duocarmicina
CN106659783A (zh) * 2014-06-20 2017-05-10 艾比吉诺米克斯国际股份有限公司 Her2抗体‑药物缀合物
CN106661124A (zh) 2014-06-20 2017-05-10 荷商台医(有限合伙)公司 抗叶酸受体α(FRA)抗体‑药物缀合物及其使用方法
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
HUE053799T2 (hu) 2015-07-10 2021-07-28 Byondis Bv Antitest-duokarmicin gyógyszer-konjugátumokat tartalmazó készítmények
HUE053614T2 (hu) 2015-09-22 2021-07-28 Byondis Bv T-DM1 refrakter rákos páciensek SYD985 kezelése
CN107029242A (zh) 2015-11-03 2017-08-11 财团法人工业技术研究院 抗体药物复合物及其制造方法
AU2016358854B2 (en) * 2015-11-24 2023-02-02 Byondis B.V. Anti-5T4 antibodies and antibody-drug conjugates
JP7078536B2 (ja) 2016-01-08 2022-05-31 アルトゥルバイオ， インコーポレイテッド 四価抗ｐｓｇｌ－１抗体とその使用
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
SG11201809830WA (en) 2016-02-12 2018-12-28 Synthon Biopharmaceuticals Bv Selective reduction of cysteine-engineered antibodies
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
ES2902179T3 (es) * 2016-08-19 2022-03-25 Bristol Myers Squibb Co Compuestos de seco-ciclopropapirroloindol, conjugados de anticuerpo-fármaco de los mismos y métodos de elaboración y uso
EP3525826B1 (en) 2016-10-11 2020-07-22 Byondis B.V Non-linear self-immolative linkers and conjugates thereof
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
ES2853999T3 (es) * 2016-11-14 2021-09-20 Byondis Bv Proceso para la preparación de alpha, omega-diamino alcanos mono-protegidos
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP3612537B1 (en) 2017-04-18 2022-07-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN110831976A (zh) 2017-05-23 2020-02-21 斯索恩生物制药有限公司 用于制备抗体-药物缀合物的双重缀合方法
RS62928B1 (sr) 2017-08-18 2022-03-31 Medimmune Ltd Konjugati pirolobenzodiazepina
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US20200345863A1 (en) 2017-10-23 2020-11-05 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
CN111556870B (zh) * 2017-11-24 2023-09-29 拜奥迪斯私人有限公司 用于合成接头-药物vc-seco-duba的改进方法
CN111727075B (zh) 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN113164447A (zh) 2018-10-15 2021-07-23 默克专利股份公司 利用dna烷化剂和atr抑制剂的组合疗法
CA3118788A1 (en) 2018-11-09 2020-05-14 Carolus Johannes Edgar VAN DEN HOEF Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods
ES2967878T3 (es) 2019-03-15 2024-05-06 Medimmune Ltd Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2021156289A1 (en) 2020-02-06 2021-08-12 Byondis B.V. Combination containing a duocarmycin derivative-comprising antibody-drug conjugate and thiosulfate
KR20230035332A (ko) 2020-07-06 2023-03-13 비온디스 비.브이. 항엽산제 링커-약물 및 항체-약물 접합체
US20220008511A1 (en) * 2020-07-12 2022-01-13 Henry J. Smith Tumor treatment using cytokines and cancer drugs
CN114867481A (zh) * 2020-07-27 2022-08-05 艾斯法姆生物技术股份有限公司 与cd151相关的兽医学疾患的治疗
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
BR112023020801A2 (pt) 2021-04-08 2023-12-12 Byondis Bv Anticorpo ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação de um anticorpo ou fragmento de ligação ao antígeno, um conjugado anticorpo-fármaco ou uma composição farmacêutica
JP2024524363A (ja) 2021-06-28 2024-07-05 ビョンディス・ビー．ブイ． ホスホ抗原を含む複合体及び治療における使用
KR20240040099A (ko) * 2021-11-02 2024-03-27 맙플렉스 인터내셔널 컴퍼니 리미티드 Sn38을 포함하는 항체-약물 접합체 중간체 및 그의 제조 방법
EP4457229A1 (en) 2021-12-30 2024-11-06 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
US20250136717A1 (en) 2022-05-16 2025-05-01 Byondis B.V. Novel masked antibodies
JP2026502845A (ja) 2022-12-22 2026-01-27 ビョンディス・ビー．ブイ． ホスホ抗原を含む新規なリンカー－薬物、新規な複合体及び治療におけるその使用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0065360A3 (en) 1981-05-12 1983-08-10 Schlumberger Electronics (U.K.) Limited Parallel motion displacement transducers
CA1238907A (en) 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
US4771128A (en) 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
MX9203200A (es) 1986-12-19 1992-09-01 Upjohn Co Analogos de cc. 1065 novedosos.
JP3380237B2 (ja) 1988-09-12 2003-02-24 ファルマシア・アンド・アップジョン・カンパニー ２のｃｐｉサブユニットを有する新規ｃｃ―１０６５アナログ類
KR100208957B1 (ko) 1990-04-25 1999-07-15 로렌스 티. 마이젠헬더 신규한 cc-1065 유사체
CA2076465C (en) * 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
JP3514490B2 (ja) * 1992-08-21 2004-03-31 杏林製薬株式会社 トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
JP3565559B2 (ja) 1994-04-01 2004-09-15 協和醗酵工業株式会社 Ｄｃ−８９誘導体
JPH07309761A (ja) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
DE19503320A1 (de) 1995-02-02 1996-08-08 Boehringer Mannheim Gmbh Neue Benzodiazepinkonjugate
US5646298A (en) 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
GB9516943D0 (en) 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
NZ321172A (en) 1995-10-03 2000-02-28 Scripps Research Inst CBI analogs of CC-1065 and the duocarmycins
EP0888301B1 (en) 1996-03-08 2005-08-10 The Scripps Research Institute Mcbi analogs of cc-1065 and the duocarmycins
US5843937A (en) * 1996-05-23 1998-12-01 Panorama Research, Inc. DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents
US6060608A (en) 1996-05-31 2000-05-09 The Scripps Research Institute Analogs of CC-1065 and the duocarmycins
DE69734722T2 (de) 1996-09-12 2006-07-20 Auckland Uniservices Ltd. Kondensierte n-acylindole als antitumormittel
GB9625913D0 (en) 1996-12-13 1997-01-29 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their seco precursors,and their use as prodrugs
WO1998025900A1 (en) 1996-12-13 1998-06-18 Shionogi & Co., Ltd. Compounds having antitumor activity
JP2002503228A (ja) 1997-05-22 2002-01-29 ザ スクリップス リサーチ インスティテュート デュオカルマイシンおよびｃｃ−１０６５の類似体
WO1999019298A1 (en) 1997-10-14 1999-04-22 The Scripps Research Institute iso-CBI AND iso-CI ANALOGS OF CC-1065 AND THE DUOCARMYCINS
US20030036629A1 (en) 1997-12-12 2003-02-20 Barry Foster Novel tgf-beta protein purification methods
AU2001273983A1 (en) 2000-05-02 2001-11-12 Lutz F. Tietze Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo(3,2-e)indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo(f)quinoline derivatives for use in selective cancer therapy
WO2001083482A1 (en) 2000-05-03 2001-11-08 The Scripps Research Institute Dna alkylating agent and activation thereof
DK1320522T3 (da) 2000-09-19 2006-04-03 Moses Lee Achirale analoger af CC-1065 og af duocarmyciner samt præparater og metoder til anvendelse deraf
US7064117B2 (en) 2001-01-24 2006-06-20 Auckland Uniservices Limited Anti-cancer 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium
US7192977B2 (en) 2001-02-22 2007-03-20 School Of Pharmacy Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
DE60220057T2 (de) 2001-02-22 2008-01-10 School Of Pharmacy, University Of London Indoline und Tetrahydrochinoline als Prodrugs zur Tumorbehandlung
JP2004529887A (ja) 2001-02-22 2004-09-30 スクール オブ ファーマシー， ユニヴァーシティ オブ ロンドン 腫瘍治療のためのプロドラッグとしてのピロロ−インドールおよびピロロ−キノリン誘導体
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7087600B2 (en) 2001-05-31 2006-08-08 Medarex, Inc. Peptidyl prodrugs and linkers and stabilizers useful therefor
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP1423110A4 (en) 2001-09-07 2005-04-27 Scripps Research Inst CBI ANALOGUE OF CC-1065 AND DUOCARMYCINES
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
WO2003097635A1 (en) 2002-05-17 2003-11-27 Auckland Uniservices Limited Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl(amine-derived)] compounds and analogues thereof, and to products obtained therefrom
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
JP5576007B2 (ja) 2003-01-27 2014-08-20 エンドサイト・インコーポレイテッド ビタミン受容体結合性薬剤送達結合体
WO2004069201A2 (en) * 2003-02-03 2004-08-19 Medlogics Device Corporation Compounds useful in coating stents to prevent and treat stenosis and restenosis
DK1594542T3 (da) 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
WO2004101767A2 (en) 2003-05-13 2004-11-25 The Scripps Research Institute Cbi analogues of the duocarmycins and cc-1065
WO2005032594A2 (en) * 2003-10-03 2005-04-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alkylators linked to polyamides as dna binding agents
US7282590B2 (en) 2004-02-12 2007-10-16 The Research Foundation Of State University Of New York Drug conjugates
CA2558399C (en) 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2005105154A1 (en) 2004-04-21 2005-11-10 Alza Corporation Polymer conjugate releasable under mild thiolytic conditions
US20050239864A1 (en) 2004-04-23 2005-10-27 Yuqiang Wang Novel tumor-selective chemotherapeutic agents
US7517903B2 (en) * 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
CN101010106A (zh) 2004-06-30 2007-08-01 诺瓦提斯公司 抗体和Duocarmycin衍生物的缀合物作为抗肿瘤剂
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
AU2005289453A1 (en) 2004-09-27 2006-04-06 Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health Modulating MxA expression
NZ536107A (en) * 2004-10-22 2007-06-29 Auckland Uniservices Ltd Nitrobenzindoles and their use in cancer therapy
WO2006090261A1 (en) 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
FR2884252B1 (fr) * 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
AU2006294554B2 (en) * 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
CN101365679B (zh) * 2005-10-26 2012-11-14 梅达莱克斯公司 制备cc-1065类似物的方法和化合物
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
US8940784B2 (en) 2006-02-02 2015-01-27 Syntarga B.V. Water-soluble CC-1065 analogs and their conjugates
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
US7695929B2 (en) 2006-11-01 2010-04-13 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
AU2007333098A1 (en) * 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind CD70 and uses thereof
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
KR20090122439A (ko) 2007-02-21 2009-11-30 메다렉스, 인코포레이티드 단일 아미노산을 갖는 화학적 링커 및 이의 접합체
ES2433379T3 (es) 2007-08-01 2013-12-10 Syntarga B.V. Análogos de CC-1065 sustituidos y sus conjugados
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2009064913A1 (en) * 2007-11-13 2009-05-22 The Scripps Research Institute Chimer containing a targeting portion linked to a scission-activated duocarmycin-type prodrug
MX2010005683A (es) 2007-11-30 2010-06-11 Bristol Myers Squibb Co Conjugados de anticuerpos anti-rg-1.
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
AR069903A1 (es) 2007-11-30 2010-03-03 Medarex Inc Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
US20090162372A1 (en) * 2007-11-30 2009-06-25 Medarex, Inc. Fibronectin ed-b antibodies, conjugates thereof, and methods of use
EP2281006B1 (en) 2008-04-30 2017-08-02 Immunogen, Inc. Cross-linkers and their uses
NZ571028A (en) 2008-09-03 2011-01-28 Auckland Uniservices Ltd Nitrobenzindole compounds and their use in cancer treatment
US8546425B2 (en) * 2008-09-17 2013-10-01 Purdue Research Foundation Folate receptor binding conjugates of antifolates
MX2011004625A (es) * 2008-11-03 2011-07-20 Syntarga Bv Analogos cc-1065 novedosos y sus conjugados.
US8507195B2 (en) 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
CA2956934C (en) 2010-04-21 2019-07-09 Syntarga B.V. Novel conjugates of cc-1065 analogs and bifunctional linkers
EP3483611B1 (en) 2011-09-29 2023-01-04 Seagen Inc. Intact mass determination of protein conjugated agent compounds
PT4241849T (pt) 2011-10-14 2024-10-30 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
MX368396B (es) 2014-01-10 2019-10-01 Synthon Biopharmaceuticals Bv Conjugados de anticuerpo-farmaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada.
AU2015205574B2 (en) 2014-01-10 2019-08-15 Byondis B.V. Method for purifying Cys-linked antibody-drug conjugates
HRP20160797T1 (hr) 2014-01-10 2016-08-12 Synthon Biopharmaceuticals B.V. Duokarmicin adsc, namijenjen upotrebi u liječenju raka endometrija
SG10201913977TA (en) 2014-05-22 2020-03-30 Synthon Biopharmaceuticals Bv Site-specific conjugation of linker drugs to antibodies and resulting adcs
PT3152191T (pt) 2014-06-05 2019-08-30 Synthon Biopharmaceuticals Bv Processo melhorado para preparar profármacos de duocarmicina
WO2016046173A1 (en) 2014-09-22 2016-03-31 Synthon Biopharmaceuticals B.V. Pan-reactive antibodies to duocarmycins

Also Published As

Publication number Publication date
JP2016183156A (ja) 2016-10-20
HRP20161339T1 (hr) 2016-11-18
CY1124632T1 (el) 2022-03-24
EP2560645A2 (en) 2013-02-27
RU2016101244A (ru) 2017-07-21
PL2560645T3 (pl) 2017-01-31
US20180147289A9 (en) 2018-05-31
RU2730502C2 (ru) 2020-08-24
AU2011243294C1 (en) 2015-12-03
BR112012026953A8 (pt) 2022-11-22
AU2011243294B2 (en) 2015-06-04
JP2013525347A (ja) 2013-06-20
US9629924B2 (en) 2017-04-25
RU2012149448A (ru) 2014-05-27
EP3056203B1 (en) 2017-12-13
CN106749665B (zh) 2021-03-26
EP3108886A2 (en) 2016-12-28
HUE050508T2 (hu) 2020-12-28
UA112291C2 (uk) 2016-08-25
CY1119893T1 (el) 2018-06-27
HRP20201446T1 (hr) 2021-03-05
BR112012026953A2 (pt) 2018-07-10
KR20180029083A (ko) 2018-03-19
RU2578719C2 (ru) 2016-03-27
JP6009434B2 (ja) 2016-10-19
PT3108886T (pt) 2020-08-27
TR201802539T4 (tr) 2018-03-21
US20180133316A9 (en) 2018-05-17
CA2956934C (en) 2019-07-09
EP3108886B1 (en) 2020-06-17
EP3056203A1 (en) 2016-08-17
ZA201208282B (en) 2014-01-29
DK3056203T3 (da) 2018-01-29
US20170274090A1 (en) 2017-09-28
AU2011243294A1 (en) 2012-11-15
CY1118072T1 (el) 2017-06-28
EP2560645B1 (en) 2016-07-13
MX336853B (es) 2016-01-19
KR20130066622A (ko) 2013-06-20
LT3056203T (lt) 2018-03-26
PT2560645T (pt) 2016-10-24
ES2594952T3 (es) 2016-12-27
KR101747478B1 (ko) 2017-06-14
RU2578719C9 (ru) 2016-10-10
CA2796712A1 (en) 2011-10-27
AU2015213336B2 (en) 2016-07-21
US20170333567A1 (en) 2017-11-23
US20130224227A1 (en) 2013-08-29
AU2015213336A1 (en) 2015-09-03
US11052155B2 (en) 2021-07-06
MX2012012176A (es) 2012-12-17
HUE030846T2 (en) 2017-06-28
CN103118679A (zh) 2013-05-22
HUE036912T2 (hu) 2018-08-28
KR20170027880A (ko) 2017-03-10
KR101901555B1 (ko) 2018-09-21
WO2011133039A2 (en) 2011-10-27
DK2560645T3 (en) 2016-10-10
ES2815678T3 (es) 2021-03-30
PL3108886T3 (pl) 2021-01-11
ES2660428T3 (es) 2018-03-22
MX374267B (es) 2025-03-06
HRP20201446T8 (hr) 2021-08-20
DK3108886T3 (da) 2020-08-10
JP6193433B2 (ja) 2017-09-06
PT3056203T (pt) 2018-02-15
LT2560645T (lt) 2016-10-10
CA2956934A1 (en) 2011-10-27
HRP20180209T1 (hr) 2018-03-09
WO2011133039A3 (en) 2012-04-12
RU2016101244A3 (lt) 2019-07-24
CA2796712C (en) 2017-02-28
NO3056203T3 (lt) 2018-05-12
EP3108886A3 (en) 2017-03-22
CN106749665A (zh) 2017-05-31
PL3056203T3 (pl) 2018-06-29

Similar Documents

Publication Publication Date Title
HRP20201446T8 (hr) Konjugati analoga cc-1065 i bifunkcionalnih veznika
PT2344478T (pt) Análogos de cc-1065 e seus conjugados
IL222269A (en) Target-targeted pyrolobenzodiazepine couplings
LT3342785T (lt) Linkeriai skirti antikūno-vaisto konjugatams
IL225200A0 (en) Amatoxin conjugates with improved linkers
SI2528625T1 (sl) Pirolobenzodiazepini in njihovi konjugati
ZA201208525B (en) Antibodies to human gdf8
PL2582728T3 (pl) Koniugaty ludzkie przeciwciało-lek przeciwko czynnikowi tkankowemu
ZA201304541B (en) Coffe capsule
SG10201608138RA (en) Human antibodies and antibody-drug conjugates against cd74
EP2575887A4 (en) CONJUGATES OF OPTIMIZED MEDICINES
ZA201407213B (en) Efficient synthesis of ethylenedicysteine-sugar conjugates for imaging and therapy
GB201010500D0 (en) Therapeutic conjugates
IL220249A0 (en) Therapeutic use of protein-polymer conjugates
GB0900539D0 (en) Modified linkers
GB201005204D0 (en) Improvements in heterotypic formulations of anticancer drugs
TWM386795U (en) Structure of containing bag
GB201016884D0 (en) Multi-case
GB0921043D0 (en) Improvements to high walled enclosed stadia